prostate cancer: insurance problems and critical illness

17/04/2016

1

Prostate cancer: insurance problems and critical illness

Tommaso Ciro Camerota, MD, Urologist, PhD studentResponsible of Urology at IRCCS Salvatore Maugeri Foundation, Pavia

University of Milan IRCCS Salvatore Maugeri Foundation Victor BabeŞ University Timisoara

1

May 25th, 2016

17/04/2016

2

Prostate

17/04/2016

3

3

Prostate

17/04/2016

4

‐ Male sex accessory gland

‐ Contributes secretions to ejaculate

‐ Growth under androgenic hormones control

4

Normal function

17/04/2016

5

Prostate cancer is nowadays the first malignancy in male population, with an increasedincidence since 1986 (FDA approval of PSA serum test).

5

Trends in incidence ratesmale population1975‐2010

Siegel R et al. Cancer Statistics 2014. CACancer J Clin 2014;64:9‐29

Epidemiology

17/04/2016

6

Afro‐american population: 149/100.000/year

Caucasian population: 107/100.000/year

Asiatic population: 28/100.000/year

6

Epidemiology

17/04/2016

7

Prostate cancer is nowadays the first malignancy in male population, with an increasedincidence since 1986 (FDA approval of PSA serum test).

7


Epidemiology

17/04/2016

8

8


Epidemiology

17/04/2016

9

Prostatic cancer is mostly diagnosed in early stages, increasingly in young Patients (50‐60 years‐old).

9

Siegel R et al. Cancer Statistics 2014.CA Cancer J Clin 2014;64:9‐29

Stage distribution at diagnosismale population, 2003‐2009

Epidemiology

Siegel R et al. Cancer Statistics 2016.CA Cancer J Clin 2016;66:7‐30

Stage distribution at diagnosismale population, 2005‐2011

17/04/2016

10

Death rates from prostate cancer are low.

10


Epidemiology

17/04/2016

11

Death rates from prostate cancer are decreasing.

11


Epidemiology

17/04/2016

12

Death rates from prostate cancer are low.

12


Five‐year relative survival rates at diagnosismale population, 2005‐2011

Epidemiology

70% of deaths due toprostate cancer occur afterage 75 years.

SEER Cancer Statistic Review, 1975‐2008, Bethesda, National CancerInstitute

17/04/2016

13

2014 SIUrO (Italian Society for Uro‐Oncology)

2015 expectations data for Italy: 323.000 persons with a diagnosis of PCa 35.000 new cases/year 1/16 men over 50 years is at risk of disease 50% of the new cases are low risk diseases (active surveillance)

13

Epidemiology

17/04/2016

14

14Source: Gapminder www.gapminder.org

Fonti‐ World Bank‐ WHO‐ UN‐ FAO‐ UNESCO‐ OECD‐ UNAIDS‐ IARC‐ UNICEF‐ The Lancet‐ et al.

Epidemiology

17/04/2016

15


Epidemiology

Italy

Japan

Australia

USEthnic and geneticbackground

17/04/2016

16


Epidemiology

Italy

US

Overdiagnosis

17/04/2016

17

Mostly an asymptomatic disease detected by

‐ Digital rectal examination

‐ PSA test (total, ratio, PSA density, PSA velocity)

‐ Transrectal ultrasound‐guided prostate biopsy

17

Diagnosis

17/04/2016

18

‐ Hypoechoic nodule at transrectal ultrasound

PROBABILITY OF GETTING PROSTATE CANCER DIAGNOSIS

18

Diagnosis

High PSA Normal PSA

DRE + 71% 26%

DRE ‐ 34% 6%

17/04/2016

19

‐ Serum PSA level

‐ Gleason score

‐ CT scan

‐ Endorectal coil MRI

‐ Bone scan

‐ Choline PET‐CT

19

Staging

17/04/2016

20

20

PCa stages

17/04/2016

21

21

PCa stage migration

Data collected from 1.317 radical prostatectomies aged 50‐80 yrs, 1983‐2003

17/04/2016

22

22

PCa stage migration

Ward JF et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome. BJU Int 2005;95:751‐6

cT1c

cT3

cT1c PSA increaseNo nodule

Bioptic detection

17/04/2016

23

‐ (Watchful waiting)

‐ Active surveillance

‐ (Focal Treatment)

‐ Radical prostatectomy (open, RALP, laparoscopic)

‐ Radiation therapy (conventional external beam vs three‐dimensionalconformal RT vs intensity‐modulated RT vs tomotheraphy vsbrachytherapy)

‐ (Hormonotheraphy)

23

TreatmentLocalized disease

17/04/2016

24

Focal Treatment

24

TreatmentLocalized disease

Van den Bos W et al. Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design.Eur Urol 2014;65:1078–83

17/04/2016

25

Da Vinci Surgical System (Intuitive) price between $1.5 and $2.5 million per machine annual maintenance ($150 000)

‐ RRP costs ranged from $ 4.075 to $ 6.296‐ RALP/LRP costs ranged from $ 5.058 to $ 11.806

No differences in continence, potency and positive margins bysurgical approach.

25

TreatmentLocalized disease ‐ costs

Ficarra V, Novara G, Artibani W, et al. Retropubic, laparoscopic, and robot‐assisted radical prostatectomy: asystematic review and cumulative analysis of comparative studies. Eur Urol 2009;55:1037–63

17/04/2016

26

Cost effectiveness of new technologies should be assessed beforewidespread adoption. To date, in the lone study to evaluate this,RALP was not found to be cost effective from a health care,economic standpoint.

26

TreatmentLocalized disease ‐ costs

Bolenz C et al. Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol 2014;65:316–24

17/04/2016

27

The most consistent benefits of LRP and RALP across multiplestudies include lower blood loss, fewer transfusions, and a shorterLOS. From a patient perspective, however, RALP often induces highexpectations for improved outcomes, mainly regarding erectilefunction recovery, and RALP has been associated with greaterdissatisfaction likely because of higher expectations for a new andbetter procedure compared to RRP.

27

TreatmentRALP

Schroeck FR, Krupski TL, Stewart SB, et al. Pretreatment expectations of patients undergoing robotic assistedlaparoscopic or open retropubic radical prostatectomy. J Urol 2012;187:894–8.

Schroeck FR, Krupski TL, Sun L, et al. Satisfaction and regret after open retropubic or robot‐assisted laparoscopicradical prostatectomy. Eur Urol 2008;54:785–93

17/04/2016

28

28

TreatmentAdvanced disease

17/04/2016

29

29

TreatmentAdvanced disease ‐ costs

Costs do not include physician fees and treatment of adverse events.

17/04/2016

30

The initial treatment costs per patient, which included the cost of biopsyand subsequent surgical or nonsurgical treatment, were € 3171 in the UK,€ 4057 in Germany, € 5851 in France, € 5226 in Italy and € 3256 in Spain.

30

TreatmentPCa economic burden

Fourcade RO et al. Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illnessstudy for France, Germany, Italy, Spain and the UK . BJU Int 2010;105:49–56

17/04/2016

31

DRG (diagnosis‐related groups) ‐ unit costs for RP ≈

€2000 in the UK€ 2600–3700 in Germany€ 3500–4500 in Spain

€ 4800 in Italy€ 6500 in France

31



17/04/2016

32

Mean direct costs of the first year after diagnosis, by stage.

32



17/04/2016

33

The total costs for all diagnosed patients in the first year after diagnosiswere € 116.7 million (UK), € 179 million (Germany), € 167.5 million(France), € 106.7 million (Italy) and € 114.6 million (Spain).

The estimated cost per patient in Italy was € 6600.

Total 5‐year costs, including costs of both diagnosis and treatment ofprostate cancer were € 269 million (UK), € 618 million (France), € 486million (Germany), € 364 million (Italy) and € 198 million (Spain).

33


1. Fourcade RO et al. Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study forFrance, Germany, Italy, Spain and the UK . BJU Int 2010;105:49–56

2‐ Lazzaro C et al. Managing patients with prostate cancer in Italy during the first year after diagnosis. A cost descriptionbased on a sample of 8 urological wards . Arch Ital Urol Androl 2003;75:138–49

3. Fourcade RO et al. Long term costs of prostate cancer: estimates for France, Germany, Italy, Spain and the UK. BJU Int2010 ; 105 : 49 – 56

17/04/2016

34

Prostate cancer is a clinically heterogeneous disease.

Autopsy studies have shown that approximately one third of menaged 40 to 60 years have histologically evident prostate cancer.

The proportion increases to as high as 75% in men older than 85years.

Most cases represent microscopic, well‐differentiated lesions thatare unlikely to be clinically important.

34

Prostate cancer

1. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of theprostate in young male patients. J Urol. 1993;150:379‐85

2. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859‐64

17/04/2016

35

Adequate evidence shows that:‐ up to 5 in 1000 men will die within 1 month of prostate cancer

surgery‐ between 10 and 70 men will have serious complications but

survive.

Critical illness or chronic disease?

35

Prostate cancer

17/04/2016

36

According to the most recent data, when including all stages ofprostate cancer:

The relative 5‐year survival rate is almost 100%

The relative 10‐year survival rate is 99%

The relative 15‐year survival rate is 94%

36

Survival

17/04/2016

37

37

Survival

Stage 5‐year relative survival rate

Local Nearly 100%

Regional Nearly 100%

Distant 28%

American Cancer Society, 2014

17/04/2016

38

1. Familiar clusters of prostate cancer (genetic predisposition)2. Environmental factors cause wide geographic variation (diet rich in animal fats and

meats and poor in fruits and vegetables)3. Chronic or recurrent inflammation4. Tobacco/alcohol5. Viral infections ?

38

1. Morganti G et al. Recherches clinicostatistiques et genetiques sur les neoplasies de la prostate. Acta Gent 1956;6:304‐52. Mandair D et al. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr

Metab 2014;11:303. Nelson WG. Prostate Cancer. N Engl J Med 2003; 349:366‐381

PCa risk factors

17/04/2016

39

Primary ‐ prevent the onset of specific diseases via risk reduction: by alteringbehaviours or exposures that can lead to disease, or by enhancing resistance tothe effects of exposure to a disease agent (eg: smoking cessation, vaccination,ecc).

Secondary ‐ procedures that detect and treat pre‐clinical pathological changesand thereby control disease progression. Screening procedures (eg:mammography).

Tertiary ‐ once a disease has developed and has been treated in its acuteclinical phase, it seeks to soften the impact caused by the disease on thepatient’s function, longevity, and quality of life (eg: cardiac rehabilitationfollowing a myocardial infarction).

39

Prevention

17/04/2016

40

40

Prevention

Cuzick J et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014 Oct;15(11):e484‐92

17/04/2016

41

Increase consumption of fruits and vegetables, reduce consumption of red meat,saturated fats.

41

PreventionLifestyle

17/04/2016

42

Prostate Cancer Prevention Trial (PCPT)‐ 18.882 men, PSA of 3.0ng/mL or less, normal digital rectal examination‐ randomization: treatment with finasteride 5mg/day or placebo‐ PSA elevation or abnormal rectal examination prostate biopsy‐ at the end of the treatment period, a prostate biopsy was planned for all men‐ study closed 15 months before (9060 men evaluable)

Results‐ PCa in 18.4% of men treated with finasteride versus 24.4% in the placebo group‐ High grade PCa more frequent in the finasteride group (effective in low risk PCa or

increasing the risk?)‐ Side effects of finasteride treatment (reduced ejaculate volume, erectile dysfuntion,

loss of libido, gynecomastia)

42

PreventionReduce inflammation

Thompson IM et al. The influence of finasteride on the development of prostate cancer. NEng J Med 2003;349:215‐24

17/04/2016

43

Prostate Cancer Prevention Trial (PCPT) – updateResults‐ 10‐year overall survival was the same for men in the finasteride group (79.3 percent)

and the men in the placebo group (79.5 percent)

43


Thompson IM et al. Long‐term survival of participants in the prostate cancer preventiontrial. N Eng J Med 2013;369:603‐10

17/04/2016

44

Prostate Cancer Prevention Trial (PCPT) – updateResults

The difference in prostate cancer diagnoses was entirely due to fewer low‐gradeprostate cancers in the finasteride arm (Gleason score 2‐6) Patients suitable foractive surveillance protocol.

44


Thompson IM et al. Long‐term survival of participants in the prostate cancer preventiontrial. N Eng J Med 2013;369:603‐10

Finasteride group

n = 9.423PCa cases = 989

High‐grade PCa = 333

Placebo group

n = 9.457PCa cases = 1,412

High‐grade PCa = 286

17/04/2016

45

SELECT study‐ prospective, randomized, placebo‐controlled clinical trial‐ Selenium and Vitamin E‐ Over 35.000 men, age 50 and older

Results‐ September 2008: selenium and vitamin E, taken alone or together for an average of

five and a half years, did not prevent prostate cancer.

‐ In 2011, men taking vitamin E had a 17 percent increased risk of prostate cancercompared to men taking the placebo.

‐ In 2014, men who started the trial with high levels of selenium doubled their risk ofdeveloping a high‐grade prostate cancer by taking selenium supplements and menwho had low levels of selenium at the start of the trial doubled their risk of high‐grade prostate cancer by taking vitamin E.

45


17/04/2016

46

‐ Diagnosis of disease

‐ Reduction in mortality

‐ Costs/benefits ratio

‐Mantaining quality of life

46

Ideal screening

17/04/2016

47

47

Moyer VA et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendationstatement. Ann Intern Med 2012;157(2):120‐34

U.S. Preventive Services Task Force Reccomendation Statement

Screening

17/04/2016

48

48

Screening goal

The primary goal of prostate cancer screening is to reducedeaths due to prostate cancer and, thus, increase length oflife.

An additional important outcome would be a reduction inthe development of symptomatic metastatic disease.

17/04/2016

49

49

Screening

Men with screen‐detected cancer can potentially fall into 1of 3 categories:‐ those whose cancer will result in death despite early

diagnosis and treatment‐ those who will have good outcomes in the absence of

screening‐ those for whom early diagnosis and treatment improve

survival.

17/04/2016

50

50

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride onthe development of prostate cancer. N Engl J Med. 2003;349:215‐24

Screening

The number of cancer cases that could be detected in ascreened population is large; a single study in which meneligible for PSA screening had biopsy regardless of PSA leveldetected cancer in nearly 25% of men.

17/04/2016

51

Lifetime risk (from age 0 to age 90 years) of death from prostatecancer is 3%, and the lifetime risk of a diagnosis of prostatecancer is 17%.

Thus, in the absence of markers that accurately identify thosemen who have life‐threatening cancers, screening will result inthe overdiagnosis and overtreatment of some men.

51

Screening

17/04/2016

52

200 men need to be treated activelyover 12 years to prevent 1 prostatecancer death.

52

Screening

Wong YN et al. Survival associated with treatment vs observation of localized prostate cancer in elderlymen. JAMA 2006;296:2683‐93

17/04/2016

53

‐ European Randomized Study of Screening for Prostate Cancer(ERSPC)

‐ Prostate, Lung, Colon and Ovarian Trial (PLCO)

53

Screenings

17/04/2016

54

54

Screening

Schroder FH et al. Screening and prostate‐cancer mortality in a randomized Europen study. NEJM2009;360(13): 1320‐8

Schroder FH et al. Screening and prostate cancer mortality: results of the European Randomised Study ofScreening for Prostate Cancer (ERSPC) at 13 years of follow‐up. Lancet 2014; S0140‐6736(14)60525‐0

17/04/2016

55

55

ScreeningPCa mortality

Schroder FH et al. Screening and prostate cancer mortality: results of the European Randomised Study ofScreening for Prostate Cancer (ERSPC) at 13 years of follow‐up. Lancet 2014; S0140‐6736(14)60525‐0

162.388 men aged 55–69 years

17/04/2016

56

56

Screening

Andriole GL et al. Mortality results from a randomized prostate‐cancer screening trial. NEJM 2009;360(13): 1310‐9

17/04/2016

57

57

ScreeningPLCO

Andriole GL et al. Mortality results from a randomized prostate‐cancer screening trial. NEJM 2009;360(13):1310‐9

up, laAfter 13 years, prostate cancer cumulative incidence was approximately 11% in the screeninggroup and 10% in the control group, and prostate cancer mortality was approximately 0.4% inboth groups.

No statistically significant effect of screening.

17/04/2016

58

58

Screening

National Cancer Institute website

The infographic below depicts the benefits and harms of PSA screeningfor prostate cancer. The estimates appeared in the U.S. PreventiveServices Task Force Recommendation Statement, published July 17 inthe Annals of Internal Medicine. The estimates were based on 13‐ and11‐year follow‐up data from the Prostate, Lung, Colorectal and OvarianCancer Screening Trial and the European Randomized Study ofScreening for Prostate Cancer.

According to the two trials, the best evidence of possible benefit ofPSA screening is in men aged 55 to 69.

17/04/2016

59

59

Screening

National CancerInstitute website

Breast cancer2.000 womenshould undergomammographicscreening for 10years to avoid 1death fromdisease. In themeanwhile, 10women aretreated for falsepositive tests.

17/04/2016

60

60

Screening

National Cancer Institute website

The infographic below depicts the benefits and harms of PSA screeningfor prostate cancer. The estimates appeared in the U.S. PreventiveServices Task Force Recommendation Statement, published July 17 inthe Annals of Internal Medicine. The estimates were based on 13‐ and11‐year follow‐up data from the Prostate, Lung, Colorectal and OvarianCancer Screening Trial and the European Randomized Study ofScreening for Prostate Cancer.

According to the two trials, the best evidence of possible benefit ofPSA screening is in men aged 55 to 69.

17/04/2016

61

61



Screening

17/04/2016

62

62



Screening

17/04/2016

63

63



Screening

The USPSTF concluded that choosing not to have PSAtesting will result in a patient living a similar length of life,with little to no difference in prostate cancer–specificmortality, while avoiding harms associated with PSA testingand subsequent diagnostic procedures and treatments.

17/04/2016

64

64


Trends in incidence rates – male population, 1975‐2012

Screening

17/04/2016

65

65


Trends in death rates – male population, 1930‐2012

Screening

NO IMPACT FROM PSA TEST SCREENING!

17/04/2016

66

66

Malvezzi M et al. European cancermortality predictions for the year 2016with focus on leukaemias. Ann Oncol.2016 Apr;27(4):725‐31

Trends in death rates – male population, predictions for 2016

Screening

17/04/2016

67

67


Total number of cancer deaths averted, from 1991 to 2012

Cancer deaths in US

The blue line represents the actualnumber of cancer deaths recorded ineach year, and the red linerepresents the number of cancerdeaths that would have beenexpected if cancer death rates hadremained at their peak.

1.199.200 saved lives in 20 years

How to manage prostatecancer in this population?

17/04/2016

68

68

Bosetti C et al. Trends in mortality fromurologic cancers in Europe, 1970‐2008. EurUrol. 2011 Jul;60(1):1‐15.

Pca cancer deaths

Limitations of the study:‐ Numeric evaluation‐ No informations on death/incidence

17/04/2016

69

69

Bosetti C et al. Trends in mortality fromurologic cancers in Europe, 1970‐2008. EurUrol. 2011 Jul;60(1):1‐15.

Trend for other urological cancers

Bladder cancerTestis cancer

17/04/2016

70

70

Lu‐Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: apopulation based study. J Urol. 2004;171:2285‐90

Pca cancer deaths

In a prespecified subgroup of men aged 55 to 69 years in theERSPC trial, a small (0.09%) absolute reduction in prostate cancerdeaths was seen after a median follow‐up of 11 years. The timeuntil any potential cancer‐specific mortality benefit (should itexist) for PSA‐based screening emerges is long (at least 9 to 10years), and most men with prostate cancer die of causes otherthan prostate cancer.

17/04/2016

71

71

Heijndijk EA et al. Cost‐effectiveness of prostate cancer screening: a simulation study based on ERSPC data. JNatl Cancer Inst. 2014 Dec 13;107(1):366

Pca cancer deaths

17/04/2016

72

The PSA test may give false‐positive or false‐negative results.

A false‐positive test result occurs when a man’s PSA level is elevated butno cancer is actually present.

A false‐positive test result may create anxiety for a man and his familyand lead to additional medical procedures, such as a prostate biopsy,that can be harmful. Possible side effects of biopsies include seriousinfections, pain, and bleeding.

72

PSA limitations

17/04/2016

73

The risk for prostate cancer among men with elevated PSAlevels is lower in men with urinary symptoms than in menwithout symptoms.

Obstruction increases PSA values due to chronicinflammation and urine reflux into the gland.

73

PSA limitations

Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tractsymptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostatecancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancerand Treatment) study. BJU Int. 2008;102:1400‐6.

17/04/2016

74

74

PCa stages

17/04/2016

75

75

Overdiagnosis

17/04/2016

76

For an individual wondering whether or not he should betested, there are two simple numbers that count: 0% and100%. Either he has life‐threatening PCa or he does not. So,what should clinicians do when a man requests a PSA test?

The aforementioned population‐based estimates will not beof help. The keywords for this dilemma are risk stratification,informed consent, and shared decision making.

76

Roobol MJ, Schroder FH. The rate of overdiagnosis inextricably linked to Prostate‐specific antigen‐basedscreening for Prostate Cancer can be quantified in several ways, but what is the practicable message? EurUrol 2014;65(6):1056/7

Overdiagnosis

17/04/2016

77

A cancer diagnosis in men with shorter life expectanciesbecause of chronic diseases or age is much more likely to beoverdiagnosis.

Estimates from the 2 largest trials suggest overdiagnosisrates of 17% to 50% for prostate cancer screening.

77

Miller AB. New data on prostate‐cancer mortality after PSA screening [Editorial]. N Engl J Med.2012;366:1047‐8

Overdiagnosis

17/04/2016

78

Overdiagnosis is the detection of pseudodisease‐screening‐detected abnormalities thatmeet the pathologic definition of cancer but will never progress to cause symptoms.

The consequence of overdiagnosis is overtreatment – surgery, chemotherapy, orradiation – that provides the patient no benefits, but only adverse effects.

“Are patients informed about overdiagnosis by their physicians when discussing cancerscreening? How much overdiagnosis would they tolerate when deciding to start orcontinue screening?”

78

Overdiagnosis

Wegwarth O, Gigerenzer G. Overdiagnosis and Overtreatment: Evaluation of What Physicians Tell TheirPatients About Screening Harms. JAMA Intern Med 2013;173(22):2086‐7

17/04/2016

79

There is adequate evidence that false‐positive PSA test resultsare associated with negative psychological effects, includingpersistent worry about prostate cancer.

Men who have a false‐positive test result are more likely to haveadditional testing, including 1 or more biopsies, in the followingyear than those who have a negative test result.

Over 10 years, approximately 15% to 20% of men will have a PSAtest result that triggers a biopsy, depending on the PSAthreshold and testing interval used.

79

Overdiagnosis

Schro¨der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators.Screening and prostate‐cancer mortality in a randomized European study. N Engl J Med.2009;360:1320‐8

17/04/2016

80

In 2013

Online survey on 317 US men and women, aged 50 to 69 years population with thehighest exposure to screening programs.

Results – already underwent to screening

‐ 19.9% attended 1 routine cancer screening‐ 36.0% reported 2 screenings‐ 27.1%reported 3 or more

‐ 17.0% indicated none

80

Overdiagnosis


= 83%!!!

17/04/2016

81

Results ‐ 1

‐ only 9.5% of the individuals (n = 30) said that their physician had informed themabout the possibility of overdiagnosis and overtreatment when discussing cancerscreening

‐ eighty percent of all participants expressed the desire to be told about screeningharms before undergoing the testing

81

Overdiagnosis


17/04/2016

82

Results ‐ 2

‐ 69% of the sample indicated that they would not start screening if overdiagnosiswas as high (ie, ≥10 cases per 1 life saved) as it is in mammography and PSA testing

82

Overdiagnosis


17/04/2016

83

False messages

Even today, woman are simply told to go for mammographic screening and are given nodetailed estimates of the benefit. In the US the Food and Drug Administration’s Officeof Women’s Health leaflet (in pink) says on its first page that “Mammograms can helpsave lives.” Similarly, the American Cancer Society’s 2014 pamphlet Breast Cancer:Early Detection tells women, “Most doctors feel that early detection tests for breastcancer save thousands of lives each year, and that many more lives could be saved ifeven more women and their health care providers took advantage of these tests,” andthe National Cancer Institute’s fact sheet says, “Screening mammography can helpreduce the number of deaths from breast cancer among women ages 40 to 70,especially for those over age 50.”

In each case, no information is given about how large the benefit is!

83

Overdiagnosis

Gigerenzer G. Breast cancer screening pamphlets mislead women. BMJ 2014;348:g2636

17/04/2016

84

84

Overdiagnosis


17/04/2016

85

American Cancer Society’s 2014 Prostate Cancer fact sheet “At this time, there isinsufficient evidence to recommend for or against routine prostate cancer screeningfor average‐risk men. For this reason, the American Cancer Society does notrecommend routine screening for prostate cancer. Rather, the ACS recommendsaverage‐risk men, beginning at age 50, have the opportunity to make an informeddecision about screening after discussing the potential benefits and limitations ofprostate cancer early detection testing with a health care professional.” and theNational Cancer Institute’s fact sheet says, “Although some organizations continue torecommend PSA screening, there is widespread agreement that any man who isconsidering getting tested should first be informed in detail about the potential harmsand benefit.”

85

Overdiagnosis

17/04/2016

86

As a result, almost all women and men

have a false impression of the benefit of mammography and PSA screening respectively.

86

Overdiagnosis

17/04/2016

87

87

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Prostate‐cancer mortality at 11 years of follow‐up. N Engl J Med. 2012;366:981‐90

Reducing harms of screening

Lengthening the interval between screening tests mayreduce harms without affecting cancer mortality; the onlyscreening trial that demonstrated a prostate cancer–specific mortality benefit generally used a 2‐ to 4‐yearscreening interval.

17/04/2016

88

88

Actual recomendations for PCa testing

The American Urological Association recommends that PSA screening, in conjunctionwith a digital rectal examination, should be offered to asymptomatic men aged 40years or older who wish to be screened, if estimated life expectancy is greater than 10years.

The American Cancer Society emphasizes informed decision making for prostatecancer screening: men at average risk should receive information beginning at age 50years, and black men or men with a family history of prostate cancer should receiveinformation at age 45 years.

The American College of Preventive Medicine recommends that clinicians discuss thepotential benefits and harms of PSA screening with men aged 50 years or older,consider their patients’ preferences, and individualize screening decisions.

The American Academy of Family Physicians is in the process of updating its guideline,and the American College of Physicians is currently developing a guidance statementon this topic.

17/04/2016

89

89

Actual recomendations for PCa testing

17/04/2016

90

Economical and social costs linked to: long‐term survival rates of PCa patients

90

Open questions

17/04/2016

91

91

Cancer survivors

De Santis CE et al. Cancer Treatment and Survivorship Statistics, 2014. CA Cancer J Clin2014;64:252‐271

17/04/2016

92

Economical and social costs linked to: long‐term survival rates of PCa patients side effects of treatments (which – in some cases – are not

affecting survival rates of PCa patients)

92

Open questions

17/04/2016

93

Other than the oncological control of disease, the preservation of pelvic functions is amajor goal of radical surgical procedures (the precise location of nerves is still unclear).

93

Side effects

Resnick MJ et al. Long‐term functional outcomes after treatment forlocalized prostate cancer. N Eng J Med 2013;368(5):436‐45

17/04/2016

94

Other than the oncological control of disease, the preservation of pelvic functions is amajor goal of radical surgical procedures (the precise location of nerves is still unclear).

94

Resnick MJ et al. Long‐term functional outcomes after treatment forlocalized prostate cancer. N Eng J Med 2013;368(5):436‐45

Side effects

17/04/2016

95


affecting survival rates of PCa patients) tailored evaluation. Not all patients (40 versus 70 years‐old)

and not all the diseases are equivalent (Gleason score, TNM,histotype, ecc).

95

Open questions

17/04/2016

96


affecting survival rates of PCa patients) tailored evaluation. Not all patients (40 versus 70 years‐old)

and not all the diseases are equivalent (Gleason score, TNM,histotype, ecc)

aging population.

96

Open questions

17/04/2016

97

97

Open questions

EUROSTAThttp://ec.europa.eu/eurostat/statistics‐explained/index.php/File:Population_structure_by_major_age_groups,_EU‐28,_2014%E2%80%9380_(%C2%B9)_(%25_of_total_population)_YB15.png (last consultation, April 17th 2016)

18.5%

28.7%

17/04/2016

98

98

Open questions

EUROSTAThttp://ec.europa.eu/eurostat/statistics‐explained/index.php/Mortality_and_life_expectancy_statistics (lastconsultation, April 17th 2016)

Economic development and the improvement in someenvironmental conditions (for example in many urban areas),improved lifestyles, advances in healthcare and medicine,including reduced infant mortality, have resulted in a continuousincrease in life expectancy at birth across Europe during the lastcentury.This process has been going on for longer in Europe than in mostother parts of the world, placing the EU‐28 among the worldleaders for life expectancy.

Life expectancy at birth in 2002: 77.7 yearsLife expectancy at birth in 2013: 80.6 years

17/04/2016

99

Individualized, risk‐stratified screening (considering factors otherthan PSA level alone such as new biomarkers, development ofnomograms and risk calculators, and suggestions forindividualized screening intervals) to avoid unnecessaryprostate biopsies and, perhaps even more important, to improveproper staging/grading of the PCa, enabling the optimal choice oftreatment.

Patients awareness!

99

Open questions

17/04/2016

100

100

May 25th, 2016

Thank You for the attention and kind invitation!

[email protected]

prostate cancer: insurance problems and critical illness

Documents